Bristol-Myers Takes Stake in Exelixis as Part of Deal to Develop Cancer Drugs | GenomeWeb

NEW YORK, July 18 - Bristol-Myers Squibb and Exelixis said Wednesday that they had signed a collaboration and licensing deal targeted at developing new cancer drugs.

Under the terms of the deal, Bristol-Myers Squibb of Princeton, NJ, will make an equity investment in Exelixis, which will use its knock-out technology to identify and validate targets that can trigger cell death in cancerous cells while leaving healthy cells unharmed. Bristol-Myers will then further analyze the targets in humans. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.